Message Font: Serif | Sans-Serif
No. of Recommendations: 3
Dear fellow Fools,
if you did not read the report of a phase 1 clinical study presented in Vienna @ ESMO2012 already posted in the Fools universe, you can find the results here:
My take is:
1) Only 14 patients were included suffering from different cancer types - this study is definitely not powered to show hard clinical outcome.
2) The 60 mg dose seems to be ideal in the Japanese study population included.
3) Tolerability looks okay although we have limited data.
But why remained only 5 out of 14 patients on study after study completion although 11 of 14 patients had decreases in tumor size compared with baseline ?
The study results are nice (be aware it was a phase 1 study), but in my opinion these results will not have any major impact on EXELs shareprice.
fool on, marsuculix
Print the post  


Live Video Event Monday!
The GP team is hosting a live video event on Monday at 4 p.m. ET. Don't worry if you can't make it — we'll have a replay and a transcript. Click for more!
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.